Positive impactCompany
Dr Reddy's stock could rise 10-15% if a major biosimilar gets approved in December: Systematix
CNBC-TV18 1 hr ago·27 Oct 2026, 6:06 am
Dr Reddy's Laboratories is a key focus for investors as Systematix predicts a potential 10-15% upside for its stock. The primary driver is the anticipated approval of a major biosimilar product in December. This specific drug is expected to be a significant revenue contributor, boosting the company's financial performance.
For investors, this development is crucial as it signals a potential catalyst for the stock. The approval could validate the company's pipeline and drive growth in its key markets. This news highlights the importance of monitoring upcoming regulatory decisions for major pharmaceutical players.
Investors should watch for the official approval announcement in December and the subsequent market reaction. The stock's movement will likely depend on the scale of the approval and the company's guidance for future sales.
Excerpt from CNBC-TV18
Published On Oct 27, 2026 | 11:36 IST Last Updated On Oct 27, 2026 | 11:36 IST Vishal Manchanda, Pharma Analyst at Systematix Group assesses the outlook for Dr Reddy’s, Mankind Pharma, Cipla and Shilpa Medicare, highlighting key drug approvals, growth challenges and potential stock triggers. Dr Reddy's Laboratories…Read the original at CNBC-TV18
Affected stocks
Bullish4 stocks
Dr. Reddy's Laboratories
DRREDDY Bullish
₹1,310.90
SHILPAMED
SHILPAMED Bullish
—
MANKIND
MANKIND Bullish
—
CIPLA
CIPLA Bullish
—
Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Dr. Reddy's Laboratories (DRREDDY).
- Category: Company.
- AI reads the tone as positive (potentially bullish) for the stock.
- Also mentions SHILPAMED, MANKIND, CIPLA.
Why it matters
A routine update for Dr. Reddy's Laboratories. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.
